MILFORD, Pa., Feb. 3, 2015 /PRNewswire/ -- Manzo
Pharmaceuticals, Inc. (OTCPink: MNZO), today announced positive
results from the six month animal study of Lacto-Freedom™, the
company's lactase producing probiotic. This successful testing
brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one
step closer to human clinical trials.
The 6-month study was conducted by Celprogen,Inc. using
laboratory rats to test the new probiotic treatment. Lab rats are
the ideal mammals to test because they are naturally lactose
intolerant. After 6 months the rats given the treatment
showed no negative side effects, even at very high doses. All
doses from low to high concentration were very successful at
colonizing the intestines and producing lactase, which enabled rats
to digest lactose. In addition, the blood glucose levels of
the rats was significantly higher after treatment, and for the full
6 months, demonstrating that the lactose in their diet was properly
broken down into glucose and galactose. This effect lasted
for a full six months after the administration of the probiotic was
discontinued. This long lasting residual effect is unique and
is far superior to any other lactose intolerance treatment option
currently on the market. Since approximately 25% of the
population in the United States is
lactose intolerant Manzo Pharmaceuticals and Celprogen are both
confident that there will be a huge demand for this product.
Manzo Pharmaceuticals, Inc. also welcomes Dean Franchino to the project. Mr. Franchino has
experience in the production of nutritional and pharmaceutical
grade products, quality control, FDA regulations, research and
development of new products and extensive knowledge of medical
equipment. This will prepare Manzo Pharmaceuticals for
the next phase of business after human trials, which will be to
manufacture, package, and distribute Lacto-Freedom™ globally.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical
company engaged in the research, development, and testing of
patented and non-patented solutions and remedies. Most notably is a
patented solution for lactose Intolerance, and a natural remedy for
colic in babies. For more information follow the company on Twitter
at @manzopharma, and visit www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The Company has tried, whenever possible, to
identify these forward-looking statements using words such as
"anticipates," "believes," "estimates," "expects," "plans,"
"intends," "potential" and similar expressions. These statements
reflect the Company's current beliefs and are based upon
information currently available to it. Accordingly, such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance or achievements to differ materially
from those expressed in or implied by such statements. The Company
undertakes no obligation to update or advise in the event of any
change, addition or alteration to the information catered in this
Press Release including such forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-positive-results-from-laboratory-study-of-lacto-freedom-probiotic-300029865.html
SOURCE Manzo Pharmaceuticals, Inc.